Strong demand from Nestle for BioGaia’s Reuteri probiotic strains in the last six months has helped the Swedish probiotics specialist towards a strong H1.
BioGaia has reported significant gains in full year 2006 that tip
it into profit, thanks largely to deals for finished probiotic
products in a widening geographical sphere.
BioGaia's probiotic drops for infant gastrointestinal health are to
be available in Canada and the Middle East, as the company extends
the distribution deal that it signed this year with Ferring.
Swedish company BioGaia has announced the latest in a string of
deals for its Reuteri probiotic, this time with a distribution
agreement with Laboratoire Physcience in France and Belgium.
A raft of new agreements and some positive study results have
helped BioGaia to report promising results for full year 2005, in
which it edged SEK 8.1m (€0.86m) closer to the point where accounts
turn from red to black.
Probiotic bacteria drops appear to reduce the symptoms of colic in
breast-feeding infants and could offer a natural, more effective
alternative to conventional treatment, say researchers.
BioGaia has signed an agreement with the Indian company Uni-Sankyo,
giving it the right to produce and sell supplements containing the
Reuteri protbiotic bacteria.
Infant formula with added probiotic bacteria appeared to reduce
irritability in infants and lowered the frequency of antibiotic
use, report US researchers.
Swedish probiotics firm BioGaia has signed a three-year agreement
with Japanese marketing company Erina for the sale of its Reuteri
tablets in Japan. The tablet has been specially designed for the
Japanese market, says the company.